Is Saakshi Medtech overvalued or undervalued?

As of 22 August 2025, Saakshi Medtech's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its relative valuation stance. The company is currently considered overvalued, with a PE ratio of 72.10, an EV to EBITDA ratio of 33.18, and a Price to Book Value of 3.64. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to peers, Saakshi Medtech's PE ratio is higher than that of Tata Chemicals, which stands at 53.91, and significantly above Kirloskar Industries at 26.49. Additionally, the company's return metrics, such as ROCE at 6.70% and ROE at 5.05%, further highlight its underperformance relative to its valuation. Despite a recent one-week stock return of 8.29% compared to a 0.97% return for the Sensex, the overall trend indicates that Saakshi Medtech remains overvalued in the current market environment.